{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:57:20Z","timestamp":1793235440478,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2013131"],"award-info":[{"award-number":["2013131"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["217780"],"award-info":[{"award-number":["217780"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["237250"],"award-info":[{"award-number":["237250"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Civitan Alzheimerfondet","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12974-019-1399-2","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T10:03:14Z","timestamp":1550743394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":253,"title":["Glial activation and inflammation along the Alzheimer\u2019s disease continuum"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-6394","authenticated-orcid":false,"given":"Kaja","family":"Nordengen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn-Eivind","family":"Kirsebom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Henjum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Selnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berglind","family":"G\u00edslad\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Wettergreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje B\u00f8en","family":"Torsetnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f8ril Rolfseng","family":"Gr\u00f8ntvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut K.","family":"Waterloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars N. G.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tormod","family":"Fladby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"issue":"4","key":"1399_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1399_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347.","journal-title":"Neurology"},{"issue":"6","key":"1399_CR3","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2014;10(6):844\u201352.","journal-title":"Alzheimer's & dementia : the journal of the Alzheimer's Association."},{"issue":"3","key":"1399_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2011;7(3):270\u20139.","journal-title":"Alzheimer's & dementia : the journal of the Alzheimer's Association"},{"issue":"3","key":"1399_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia : the journal of the Alzheimer's Association. 2011;7(3):280\u201392.","journal-title":"Alzheimer's & Dementia : the journal of the Alzheimer's Association"},{"issue":"3","key":"1399_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2011;7(3):263\u20139.","journal-title":"Alzheimer's & dementia : the journal of the Alzheimer's Association."},{"issue":"1","key":"1399_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JAD-170231","volume":"60","author":"T Fladby","year":"2017","unstructured":"Fladby T, Palhaugen L, Selnes P, Waterloo K, Brathen G, Hessen E, et al. Detecting at-risk Alzheimer's disease cases. J Alzheimers Dis. 2017;60(1):97\u2013105.","journal-title":"J Alzheimers Dis"},{"key":"1399_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fneur.2015.00216","volume":"6","author":"BL Reijs","year":"2015","unstructured":"Reijs BL, Teunissen CE, Goncharenko N, Betsou F, Blennow K, Baldeiras I, et al. The central biobank and virtual biobank of BIOMARKAPD: a resource for studies on neurodegenerative diseases. Front Neurol. 2015;6:216.","journal-title":"Front Neurol"},{"key":"1399_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.conb.2015.10.004","volume":"36","author":"C Villegas-Llerena","year":"2016","unstructured":"Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Curr Opin Neurobiol. 2016;36:74\u201381.","journal-title":"Curr Opin Neurobiol"},{"issue":"2","key":"1399_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368(2):107\u201316.","journal-title":"N Engl J Med"},{"issue":"10","key":"1399_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094\u20139.","journal-title":"Nat Genet"},{"issue":"6","key":"1399_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","volume":"48","author":"JR Cirrito","year":"2005","unstructured":"Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48(6):913\u201322.","journal-title":"Neuron"},{"issue":"13","key":"1399_CR13","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1523\/JNEUROSCI.5572-08.2009","volume":"29","author":"S Mandrekar","year":"2009","unstructured":"Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, Landreth GE. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci. 2009;29(13):4252\u201362.","journal-title":"J Neurosci"},{"issue":"8","key":"1399_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457\u201370.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"1399_CR15","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nrn.2017.110","volume":"18","author":"U Neniskyte","year":"2017","unstructured":"Neniskyte U, Gross CT. Errant gardeners: glial-cell-dependent synaptic pruning and neurodevelopmental disorders. Nat Rev Neurosci. 2017;18(11):658\u201370.","journal-title":"Nat Rev Neurosci"},{"key":"1399_CR16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","volume":"35","author":"M Colonna","year":"2017","unstructured":"Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441\u201368.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"1399_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"6","key":"1399_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jalz.2014.05.1757","volume":"11","author":"International Genomics of Alzheimer\u2019s Disease Consortium (IGAP)","year":"2015","unstructured":"International Genomics of Alzheimer\u2019s Disease Consortium (IGAP). Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimers Dement. 2015;11(6):658\u201371.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1399_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.molmed.2017.03.008","volume":"23","author":"FL Yeh","year":"2017","unstructured":"Yeh FL, Hansen DV, Sheng M. TREM2, microglia, and neurodegenerative diseases. Trends Mol Med. 2017;23(6):512\u201333.","journal-title":"Trends Mol Med"},{"issue":"9","key":"1399_CR20","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1172\/JCI90606","volume":"127","author":"H Sarlus","year":"2017","unstructured":"Sarlus H, Heneka MT. Microglia in Alzheimer's disease. J Clin Invest. 2017;127(9):3240\u20139.","journal-title":"J Clin Invest"},{"issue":"3","key":"1399_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3233\/JAD-151075","volume":"51","author":"KA Southam","year":"2016","unstructured":"Southam KA, Vincent AJ, Small DH. Do microglia default on network maintenance in Alzheimer's disease? J Alzheimers Dis. 2016;51(3):657\u201369.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1399_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388\u2013405.","journal-title":"Lancet Neurol"},{"issue":"33","key":"1399_CR23","doi-asserted-by":"publisher","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","volume":"28","author":"SE Hickman","year":"2008","unstructured":"Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008;28(33):8354\u201360.","journal-title":"J Neurosci"},{"issue":"3","key":"1399_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ana.24454","volume":"78","author":"BW Patterson","year":"2015","unstructured":"Patterson BW, Elbert DL, Mawuenyega KG, Kasten T, Ovod V, Ma S, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol. 2015;78(3):439\u201353.","journal-title":"Ann Neurol"},{"issue":"Pt 4","key":"1399_CR25","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/aww017","volume":"139","author":"L Hamelin","year":"2016","unstructured":"Hamelin L, Lagarde J, Dorothee G, Leroy C, Labit M, Comley RA, et al. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139(Pt 4):1252\u201364.","journal-title":"Brain"},{"key":"1399_CR26","volume-title":"Edison P","author":"Z Fan","year":"2017","unstructured":"Fan Z, Brooks DJ, Okello A. Edison P. Brain: An early and late peak in microglial activation in Alzheimer's disease trajectory; 2017."},{"key":"1399_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fnagi.2017.00008","volume":"9","author":"M Brendel","year":"2017","unstructured":"Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, et al. Increase of TREM2 during aging of an Alzheimer's disease mouse model is paralleled by microglial activation and amyloidosis. Front Aging Neurosci. 2017;9:8.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"1399_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1084\/jem.20151948","volume":"213","author":"Y Wang","year":"2016","unstructured":"Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667\u201375.","journal-title":"J Exp Med"},{"issue":"5","key":"1399_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466\u201376.","journal-title":"EMBO Mol Med"},{"issue":"12","key":"1399_CR30","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jalz.2016.06.005","volume":"12","author":"JD Gispert","year":"2016","unstructured":"Gispert JD, Suarez-Calvet M, Monte GC, Tucholka A, Falcon C, Rojas S, et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimers Dement. 2016;12(12):1259\u201372.","journal-title":"Alzheimers Dement"},{"issue":"43","key":"1399_CR31","doi-asserted-by":"publisher","first-page":"26043","DOI":"10.1074\/jbc.M115.679043","volume":"290","author":"Y Atagi","year":"2015","unstructured":"Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem. 2015;290(43):26043\u201350.","journal-title":"J Biol Chem"},{"issue":"43","key":"1399_CR32","doi-asserted-by":"publisher","first-page":"26033","DOI":"10.1074\/jbc.M115.677286","volume":"290","author":"CC Bailey","year":"2015","unstructured":"Bailey CC, DeVaux LB, Farzan M. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem. 2015;290(43):26033\u201342.","journal-title":"J Biol Chem"},{"issue":"2","key":"1399_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","volume":"91","author":"FL Yeh","year":"2016","unstructured":"Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 binds to apolipoproteins, including APOE and CLU\/APOJ, and thereby facilitates uptake of amyloid-Beta by microglia. Neuron. 2016;91(2):328\u201340.","journal-title":"Neuron"},{"issue":"3","key":"1399_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/cne.903390307","volume":"339","author":"GM Pasinetti","year":"1994","unstructured":"Pasinetti GM, Johnson SA, Oda T, Rozovsky I, Finch CE. Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J Comp Neurol. 1994;339(3):387\u2013400.","journal-title":"J Comp Neurol"},{"issue":"1","key":"1399_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s12264-013-1391-2","volume":"30","author":"X Li","year":"2014","unstructured":"Li X, Ma Y, Wei X, Li Y, Wu H, Zhuang J, et al. Clusterin in Alzheimer's disease: a player in the biological behavior of amyloid-beta. Neurosci Bull. 2014;30(1):162\u20138.","journal-title":"Neurosci Bull"},{"issue":"2","key":"1399_CR36","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12035-012-8237-1","volume":"45","author":"JT Yu","year":"2012","unstructured":"Yu JT, Tan L. The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. Mol Neurobiol. 2012;45(2):314\u201326.","journal-title":"Mol Neurobiol"},{"key":"1399_CR37","doi-asserted-by":"crossref","unstructured":"Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, et al. A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. Neurobiol Aging. 2016;37:208.e1\u2013.e9.","DOI":"10.1016\/j.neurobiolaging.2015.09.009"},{"key":"1399_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neurobiolaging.2015.10.022","volume":"38","author":"JD Gispert","year":"2016","unstructured":"Gispert JD, Monte GC, Falcon C, Tucholka A, Rojas S, Sanchez-Valle R, et al. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol Aging. 2016;38:47\u201355.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1399_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-017-0226-4","volume":"12","author":"F Llorens","year":"2017","unstructured":"Llorens F, Thune K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12(1):83.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"1399_CR40","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/JAD-140624","volume":"42","author":"A Antonell","year":"2014","unstructured":"Antonell A, Mansilla A, Rami L, Llado A, Iranzo A, Olives J, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J Alzheimers Dis. 2014;42(3):901\u20138.","journal-title":"J Alzheimers Dis"},{"key":"1399_CR41","first-page":"8090918","volume":"2016","author":"P Chen","year":"2016","unstructured":"Chen P, Zhao W, Guo Y, Xu J, Yin M. CX3CL1\/CX3CR1 in Alzheimer's disease: a target for neuroprotection. Biomed Res Int. 2016;2016:8090918.","journal-title":"Biomed Res Int"},{"issue":"4","key":"1399_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V","volume":"29","author":"V Zujovic","year":"2000","unstructured":"Zujovic V, Benavides J, Vige X, Carter C, Taupin V. Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. Glia. 2000;29(4):305\u201315.","journal-title":"Glia"},{"issue":"1\u20132","key":"1399_CR43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0006-8993(03)02867-1","volume":"979","author":"T Mizuno","year":"2003","unstructured":"Mizuno T, Kawanokuchi J, Numata K, Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res. 2003;979(1\u20132):65\u201370.","journal-title":"Brain Res"},{"key":"1399_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1742-2094-8-9","volume":"8","author":"MM Pabon","year":"2011","unstructured":"Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation. 2011;8:9.","journal-title":"J Neuroinflammation"},{"issue":"7","key":"1399_CR45","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00702-015-1369-5","volume":"122","author":"S Strobel","year":"2015","unstructured":"Strobel S, Grunblatt E, Riederer P, Heinsen H, Arzberger T, Al-Sarraj S, et al. Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARgamma. J Neural Transm. 2015;122(7):1069\u201376.","journal-title":"J Neural Transm"},{"issue":"6","key":"1399_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","volume":"29","author":"SL Deshmane","year":"2009","unstructured":"Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interf Cytokine Res. 2009;29(6):313\u201326.","journal-title":"J Interf Cytokine Res"},{"key":"1399_CR47","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fnins.2018.00609","volume":"12","author":"JR Perea","year":"2018","unstructured":"Perea JR, Lleo A, Alcolea D, Fortea J, Avila J, Bolos M. Decreased CX3CL1 levels in the cerebrospinal fluid of patients with Alzheimer's disease. Front Neurosci. 2018;12:609.","journal-title":"Front Neurosci"},{"issue":"2","key":"1399_CR48","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jamaneurol.2013.4560","volume":"71","author":"RS Desikan","year":"2014","unstructured":"Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, et al. The role of clusterin in amyloid-beta-associated neurodegeneration. JAMA Neurol. 2014;71(2):180\u20137.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1399_CR49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13195-016-0182-1","volume":"8","author":"K Henjum","year":"2016","unstructured":"Henjum K, Almdahl IS, Arskog V, Minthon L, Hansson O, Fladby T, et al. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res Ther. 2016;8(1):17.","journal-title":"Alzheimers Res Ther"},{"key":"1399_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.neulet.2018.08.038","volume":"686","author":"D Liu","year":"2018","unstructured":"Liu D, Cao B, Zhao Y, Huang H, McIntyre RS, Rosenblat JD, et al. Soluble TREM2 changes during the clinical course of Alzheimer's disease: a meta-analysis. Neurosci Lett. 2018;686:10\u20136.","journal-title":"Neurosci Lett"},{"issue":"2","key":"1399_CR51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12017-011-8147-9","volume":"13","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Mansson JE, et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. NeuroMolecular Med. 2011;13(2):151\u20139.","journal-title":"NeuroMolecular Med"},{"issue":"1","key":"1399_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030525","volume":"7","author":"K Westin","year":"2012","unstructured":"Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One. 2012;7(1):e30525.","journal-title":"PLoS One"},{"issue":"1","key":"1399_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13195-018-0353-3","volume":"10","author":"F Brosseron","year":"2018","unstructured":"Brosseron F, Traschutz A, Widmann CN, Kummer MP, Tacik P, Santarelli F, et al. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer's disease. Alzheimers Res Ther. 2018;10(1):25.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1399_CR54","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1001\/archneur.63.4.538","volume":"63","author":"D Galimberti","year":"2006","unstructured":"Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2006;63(4):538\u201343.","journal-title":"Arch Neurol"},{"issue":"1","key":"1399_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000089137","volume":"21","author":"I Blasko","year":"2006","unstructured":"Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord. 2006;21(1):9\u201315.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"1399_CR56","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-2001-3501","volume":"3","author":"AM Lidstrom","year":"2001","unstructured":"Lidstrom AM, Hesse C, Rosengren L, Fredman P, Davidsson P, Blennow K. Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke. J Alzheimers Dis. 2001;3(5):435\u201342.","journal-title":"J Alzheimers Dis"},{"key":"1399_CR57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2015.12.023","volume":"361","author":"H Prikrylova Vranova","year":"2016","unstructured":"Prikrylova Vranova H, Henykova E, Mares J, Kaiserova M, Mensikova K, Vastik M, et al. Clusterin CSF levels in differential diagnosis of neurodegenerative disorders. J Neurol Sci. 2016;361:117\u201321.","journal-title":"J Neurol Sci"},{"issue":"2","key":"1399_CR58","first-page":"53","volume":"5","author":"JL Richens","year":"2014","unstructured":"Richens JL, Vere KA, Light RA, Soria D, Garibaldi J, Smith AD, et al. Practical detection of a definitive biomarker panel for Alzheimer's disease; comparisons between matched plasma and cerebrospinal fluid. Int J Mol Epidemiol Genet. 2014;5(2):53\u201370.","journal-title":"Int J Mol Epidemiol Genet"},{"key":"1399_CR59","doi-asserted-by":"crossref","unstructured":"Yang C, Wang H, Li C, Niu H, Luo S, Guo X. Association between clusterin concentration and dementia: a systematic review and meta-analysis. Metab Brain Dis. 2018.","DOI":"10.1007\/s11011-018-0325-0"},{"key":"1399_CR60","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014, 6, 243:243ra86."},{"issue":"1\u20132","key":"1399_CR61","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.molbrainres.2003.08.005","volume":"118","author":"M Puchades","year":"2003","unstructured":"Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003;118(1\u20132):140\u20136.","journal-title":"Brain Res Mol Brain Res"},{"key":"1399_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener. 2016;11:3.","journal-title":"Mol Neurodegener"},{"issue":"6","key":"1399_CR63","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131(6):925\u201333.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1399_CR64","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12883-016-0742-9","volume":"16","author":"Y Deming","year":"2016","unstructured":"Deming Y, Black K, Carrell D, Cai Y, Del-Aguila JL, Fernandez MV, et al. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. BMC Neurol. 2016;16(1):217.","journal-title":"BMC Neurol"},{"issue":"8","key":"1399_CR65","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.neuint.2005.12.005","volume":"48","author":"AM Nilselid","year":"2006","unstructured":"Nilselid AM, Davidsson P, Nagga K, Andreasen N, Fredman P, Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int. 2006;48(8):718\u201328.","journal-title":"Neurochem Int"},{"issue":"5 Suppl","key":"1399_CR66","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.jalz.2011.07.001","volume":"8","author":"P Selnes","year":"2012","unstructured":"Selnes P, Fjell AM, Gjerstad L, Bjornerud A, Wallin A, Due-Tonnessen P, et al. White matter imaging changes in subjective and mild cognitive impairment. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2012;8(5 Suppl):S112\u201321.","journal-title":"Alzheimer's & dementia : the journal of the Alzheimer's Association."},{"issue":"4","key":"1399_CR67","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3233\/JAD-170582","volume":"62","author":"LF Kalheim","year":"2018","unstructured":"Kalheim LF, Fladby T, Coello C, Bjornerud A, Selnes P. [18F]-Flutemetamol uptake in cortex and white matter: comparison with cerebrospinal fluid biomarkers and [18F]-Fludeoxyglucose. J Alzheimers Dis. 2018;62(4):1595\u2013607.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"1399_CR68","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/clinchem\/47.10.1776","volume":"47","author":"M Sjogren","year":"2001","unstructured":"Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001;47(10):1776\u201381.","journal-title":"Clin Chem"},{"key":"1399_CR69","volume-title":"The visual object and space perception battery","author":"EK Warrington","year":"1991","unstructured":"Warrington EK, James M. The visual object and space perception battery. Thames Valley Test Company: Bury St Edmunds, England; 1991."},{"key":"1399_CR70","volume-title":"Revised COmprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted neuropsychological norms for African American and Caucasian adults: professional manual: psychological assessment resources","author":"RK Heaton","year":"2004","unstructured":"Heaton RK. Revised COmprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted neuropsychological norms for African American and Caucasian adults: professional manual: psychological assessment resources; 2004."},{"issue":"1","key":"1399_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1600-0404.2010.01459.x","volume":"125","author":"M Sotaniemi","year":"2012","unstructured":"Sotaniemi M, Pulliainen V, Hokkanen L, Pirttila T, Hallikainen I, Soininen H, et al. CERAD-neuropsychological battery in screening mild Alzheimer's disease. Acta Neurol Scand. 2012;125(1):16\u201323.","journal-title":"Acta Neurol Scand"},{"key":"1399_CR72","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566\u201372.","journal-title":"Br J Psychiatry"},{"issue":"4","key":"1399_CR73","first-page":"661","volume":"24","author":"B Reisberg","year":"1988","unstructured":"Reisberg B, Ferris SH, de Leon MJ, Crook T. Global Deterioration Scale (GDS). Psychopharmacol Bull. 1988;24(4):661\u20133.","journal-title":"Psychopharmacol Bull"},{"issue":"10","key":"1399_CR74","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21037\/atm.2018.04.22","volume":"6","author":"JW Li","year":"2018","unstructured":"Li JW, Zong Y, Cao XP, Tan L, Tan L. Microglial priming in Alzheimer's disease. Annals of translational medicine. 2018;6(10):176.","journal-title":"Annals of translational medicine"},{"key":"1399_CR75","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fnhum.2016.00398","volume":"10","author":"L Hoeijmakers","year":"2016","unstructured":"Hoeijmakers L, Heinen Y, van Dam AM, Lucassen PJ, Korosi A. Microglial priming and Alzheimer's disease: a possible role for (early) immune challenges and epigenetics? Front Hum Neurosci. 2016;10:398.","journal-title":"Front Hum Neurosci"},{"issue":"1","key":"1399_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/187152709787601821","volume":"8","author":"D Morgan","year":"2009","unstructured":"Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets. 2009;8(1):7\u201315.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"1","key":"1399_CR77","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamapsychiatry.2017.3391","volume":"75","author":"WJ Jansen","year":"2018","unstructured":"Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, et al. Association of Cerebral Amyloid-beta Aggregation with Cognitive Functioning in persons without dementia. JAMA psychiatry. 2018;75(1):84\u201395.","journal-title":"JAMA psychiatry"},{"key":"1399_CR78","doi-asserted-by":"crossref","unstructured":"Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014;6(226):226ra30.","DOI":"10.1126\/scitranslmed.3007901"},{"issue":"18","key":"1399_CR79","doi-asserted-by":"publisher","first-page":"10896","DOI":"10.1073\/pnas.95.18.10896","volume":"95","author":"JK Harrison","year":"1998","unstructured":"Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A. 1998;95(18):10896\u2013901.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"1399_CR80","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/jnen\/62.9.899","volume":"62","author":"S Hulshof","year":"2003","unstructured":"Hulshof S, van Haastert ES, Kuipers HF, van den Elsen PJ, De Groot CJ, van der Valk P, et al. CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis. J Neuropathol Exp Neurol. 2003;62(9):899\u2013907.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"1399_CR81","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.163.3.1628","volume":"163","author":"D Maciejewski-Lenoir","year":"1999","unstructured":"Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB. Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol. 1999;163(3):1628\u201335.","journal-title":"J Immunol"},{"issue":"4","key":"1399_CR82","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/glia.10037","volume":"37","author":"PM Hughes","year":"2002","unstructured":"Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia. 2002;37(4):314\u201327.","journal-title":"Glia"},{"issue":"2","key":"1399_CR83","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0304-3940(01)01699-8","volume":"303","author":"H Yoshida","year":"2001","unstructured":"Yoshida H, Imaizumi T, Fujimoto K, Matsuo N, Kimura K, Cui X, et al. Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. Neurosci Lett. 2001;303(2):132\u20136.","journal-title":"Neurosci Lett"},{"key":"1399_CR84","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/1742-2094-9-193","volume":"9","author":"JH Mills","year":"2012","unstructured":"Mills JH, Alabanza LM, Mahamed DA, Bynoe MS. Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis. J Neuroinflammation. 2012;9:193.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1399_CR85","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.yexcr.2004.02.031","volume":"297","author":"AN Kalehua","year":"2004","unstructured":"Kalehua AN, Nagel JE, Whelchel LM, Gides JJ, Pyle RS, Smith RJ, et al. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration. Exp Cell Res. 2004;297(1):197\u2013211.","journal-title":"Exp Cell Res"},{"issue":"4","key":"1399_CR86","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/glia.20016","volume":"46","author":"MC Wittendorp","year":"2004","unstructured":"Wittendorp MC, Boddeke HW, Biber K. Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes. Glia. 2004;46(4):410\u20138.","journal-title":"Glia"},{"issue":"1","key":"1399_CR87","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/jnr.20231","volume":"78","author":"E Dicou","year":"2004","unstructured":"Dicou E, Vincent JP, Mazella J. Neurotensin receptor-3\/sortilin mediates neurotensin-induced cytokine\/chemokine expression in a murine microglial cell line. J Neurosci Res. 2004;78(1):92\u20139.","journal-title":"J Neurosci Res"},{"issue":"3","key":"1399_CR88","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/cne.20598","volume":"489","author":"G Banisadr","year":"2005","unstructured":"Banisadr G, Gosselin RD, Mechighel P, Kitabgi P, Rostene W, Parsadaniantz SM. Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1\/CCL2) in rat brain: evidence for its colocalization with neurotransmitters and neuropeptides. J Comp Neurol. 2005;489(3):275\u201392.","journal-title":"J Comp Neurol"},{"issue":"4","key":"1399_CR89","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","volume":"22","author":"D Bonneh-Barkay","year":"2012","unstructured":"Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012;22(4):530\u201346.","journal-title":"Brain Pathol"},{"issue":"22","key":"1399_CR90","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1021\/bi00474a025","volume":"29","author":"HV Silva de","year":"1990","unstructured":"de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry. 1990;29(22):5380\u20139.","journal-title":"Biochemistry"},{"issue":"3","key":"1399_CR91","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/(SICI)1098-1136(199807)23:3<221::AID-GLIA5>3.0.CO;2-7","volume":"23","author":"L Liu","year":"1998","unstructured":"Liu L, Persson JK, Svensson M, Aldskogius H. Glial cell responses, complement, and clusterin in the central nervous system following dorsal root transection. Glia. 1998;23(3):221\u201338.","journal-title":"Glia"},{"issue":"1\u20132","key":"1399_CR92","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0006-8993(01)02222-3","volume":"899","author":"S Kullberg","year":"2001","unstructured":"Kullberg S, Aldskogius H, Ulfhake B. Microglial activation, emergence of ED1-expressing cells and clusterin upregulation in the aging rat CNS, with special reference to the spinal cord. Brain Res. 2001;899(1\u20132):169\u201386.","journal-title":"Brain Res"},{"issue":"3","key":"1399_CR93","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.neuroscience.2008.06.022","volume":"155","author":"Y Charnay","year":"2008","unstructured":"Charnay Y, Imhof A, Vallet PG, Hakkoum D, Lathuiliere A, Poku N, et al. Clusterin expression during fetal and postnatal CNS development in mouse. Neuroscience. 2008;155(3):714\u201324.","journal-title":"Neuroscience"},{"issue":"2","key":"1399_CR94","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cne.903340205","volume":"334","author":"M Danik","year":"1993","unstructured":"Danik M, Chabot JG, Hassan-Gonzalez D, Suh M, Quirion R. Localization of sulfated glycoprotein-2\/clusterin mRNA in the rat brain by in situ hybridization. J Comp Neurol. 1993;334(2):209\u201327.","journal-title":"J Comp Neurol"},{"issue":"4","key":"1399_CR95","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/neu.480240402","volume":"24","author":"MK O'Bryan","year":"1993","unstructured":"O'Bryan MK, Cheema SS, Bartlett PF, Murphy BF, Pearse MJ. Clusterin levels increase during neuronal development. J Neurobiol. 1993;24(4):421\u201332.","journal-title":"J Neurobiol"},{"issue":"13","key":"1399_CR96","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/glia.20710","volume":"56","author":"S Frank","year":"2008","unstructured":"Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56(13):1438\u201347.","journal-title":"Glia"},{"issue":"4","key":"1399_CR97","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1084\/jem.20041611","volume":"201","author":"K Takahashi","year":"2005","unstructured":"Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201(4):647\u201357.","journal-title":"J Exp Med"},{"issue":"13","key":"1399_CR98","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1038\/npp.2014.164","volume":"39","author":"T Jiang","year":"2014","unstructured":"Jiang T, Tan L, Zhu XC, Zhang QQ, Cao L, Tan MS, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. Neuropsychopharmacology. 2014;39(13):2949\u201362.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"1399_CR99","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.neurobiolaging.2013.11.026","volume":"35","author":"T Jiang","year":"2014","unstructured":"Jiang T, Yu JT, Zhu XC, Tan MS, Gu LZ, Zhang YD, et al. Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol Aging. 2014;35(6):1243\u201351.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"1399_CR100","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.4049\/jimmunol.164.10.4991","volume":"164","author":"A Bouchon","year":"2000","unstructured":"Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164(10):4991\u20135.","journal-title":"J Immunol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1399-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-019-1399-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1399-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:10:08Z","timestamp":1694639408000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1399-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1399"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1399-2","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"26 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The project has been considered by the Norwegian Regional Ethics Committee (approval number for the DDI project: 2013\/115, approval number for the genetic analysis (APGEM): 2014\/1164, approval number for the biobank: 2011\/1051). The local data protection officer at Akershus University Hospital has also approved the study with the according approval number 13-056, 14-156 and 13-088. Data handling was in accordance with local and national regulations, with security precautions for storage and regulated biobank facilities. Both sexes are equally included, patients and controls give informed consent to participate in the study. The DDI has a patient and caregiver representative in the steering group. User participation is ensured with open meetings and written information.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Aarsland has received research support and\/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, and GE Health and serves as paid consultant for H. Lundbeck, Eisai, Heptares, and Axovant. Dag Aarsland is a Royal Society Wolfson Research Merit Award Holder and would like to thank the Wolfson Foundation and the Royal Society for their support. Dr. Fladby is inventor and co-founder of Inventor Pre Diagnostics A\/S. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"46"}}